DNAG-Kleiner Zock gefällig!

Könnte was werden!

USA - DNAG

Germany - A0ETWM

BB Pushed und bei dem Läuft es gerade nicht schlecht mit seinen Empfehlungen!

und von Heute

DNAG (OTCBB)

---

DNAPrint Genomics President & CEO Richard Gabriel Set for Market News First Live Interview on Friday, Aug. 18, 2006

MONDAY , AUGUST 21, 2006 07:00 AM

SARASOTA, FL -- (MARKET WIRE) -- 08/21/06 -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today
announced that President and Chief Executive Officer Richard Gabriel will
be interviewed live on Market News First on Wednesday, August 23, at 2:00
PM Eastern time.

Mr. Gabriel will provide an update on recent developments at the Company
and insights into its latest projects. The live interview can be accessed
at www.mn1.com, where it will also be archived and available for streaming.

Market News First is an online, live radio web site that brings investors
current news on the market.

<!--FIRST IMAGE PLACEHOLDER -->

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based
products and services in two primary markets: biomedical and forensics.
DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops
diagnostic tests and theranostic products (drug/test combinations) using
the Company's proprietary ancestry-informed genetic marker studies combined
with proprietary computational modeling technology. Computational Biology
and Pharmacogenomics services are also offered externally to
biopharmaceutical companies. The Company's first theranostic product is
PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of
anemia in renal dialysis patients (with end stage renal disease).
Preclinical and clinical development of all the Company's drug candidates
will benefit from simulated pre-trials to design actual trials better and
are targeted to patients with genetic profiles indicating their propensity
to have the best clinical responses. DNAPrint is proud of its continued
dedication to developing and supplying new technological advances in law
enforcement and consumer ancestry heritage interests. Please refer to
www.dnaprint.com for information on law enforcement and consumer
applications which include DNAWITNESS(TM), RETINOME(TM), ANCESTRYbyDNA(TM)
and EURO-DNA(TM). DNAWitness-Y and DNAWitness-Mito are two tests offered by
the Company. The results from these tests may be used as identification
tools when a DNA sample is deteriorated or compromised or other DNA testing
fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are
forward-looking statements. Such statements are subject to risks and
uncertainties that could cause actual results to differ materially from
those projected, including, but not limited to, uncertainties relating to
technologies, product development, manufacturing, market acceptance, cost
and pricing of DNAPrint's products, dependence on collaborations and
partners, regulatory approvals, competition, intellectual property of
others, and patent protection and litigation. DNAPrint Genomics, Inc.
expressly disclaims any obligation or undertaking, except as may be
required by applicable law or regulation to release publicly any updates or
revisions to any
forward-looking statements contained herein to reflect any change in
DNAPrint's expectations with regard thereto or any change in events,
conditions, or circumstances on which any such statements are based.

---

Company Contact:
Richard Gabriel
CEO and President
941-366-3400

-or-

Ron Stabiner
The Wall Street Group, Inc.
212-888-4848


Source: DNAPrint Genomics, Inc.

 

 

Denke fast das wir über 2cent schließen

jep  

 

und danach auchnochmal Richtig

 

jep

 

RT-0.0165

Umsatz 14,400,000

 

www.biofrontera.com

Eine deutsche Firma.

Schaut unter : Investoren

Auch da ist DNAG mit 18 % dabei!

Mehr wert als die MK derzeit.

http://www.bloomberg.com/apps/quote?ticker=dnag:US  

FUNDAMENTALS

Shares (Millions)381.316	Market Cap (Millions)6.444	Float (Millions)371.867	Return on EquityN.A.
Short Interest N.A.	Last Dividend ReportedN.A.	Dividend Yield (Trailing 12mo.)N.A.	Relative Dividend YieldN.A.

Price for DNAG:USSECTOR COMPARATIVE RETURNS

Chart the Performance of DNAG:US	DNAG:US SPX:IND

 

RT 0,017
Vol 16,381,782

+25,9%

 

 

Schluß bei 0.0166

19,402,632

bis Morgen  

die Stimmung in USA ist euphorisch, exemplarisch hier ein posting aus dem RB-Forum, möge der Mann Recht haben :-).

**************************************************

By: jr9990  
21 Aug 2006, 10:27 PM EDT
Msg. 360944 of 360958

"i been into the stock market since i was 15 and i'm 45 now. and i'm not kidding. if this is'nt that needle in the hay stack i will have to work till i'm 62."

**************************************************
 

DNAPrint Genomics Announces Strategic Alliance With NeoCodex
Company Will Provide DNA Sample Testing for Theranostic Research on Ovarian Cancer

SARASOTA, FL -- (MARKET WIRE) -- August 22, 2006 -- DNAPrint Genomics, Inc. (OTCBB: DNAG) today announced that it has signed a strategic alliance agreement with NeoCodex, Inc., of Sevilla, Spain, to provide DNA sampling for ongoing research into theranostic test/drug treatments for ovarian cancer.

Highlighted Links
MacReport.Net
DNAPrint(TM) Genomics, Inc.

Under the terms of the agreement, NeoCodex business units in Spain and in the United States will gather DNA samples that will be tested by DNAPrint Genomics for research into the effectiveness of certain treatments for ovarian cancer involving combinatorial treatments of Taxotere®, Taxol®, Carboplatin, and Cisplatin.

DNAPrint technologies will apply its Admixture Mapping (ADMIX) process to identify appropriate Ancestry Informative Markers (AIMs) within the targeted population to identify genes of further interest, based on the drug response data provided by NeoCodex.

"We are extremely pleased to collaborate with NeoCodex on this important research," stated DNAPrint President and Chief Executive Officer Richard Gabriel. "A crucial element of any chemotherapy regimen is identifying immediately the combinations of drugs that will put the cancer into remission. We are confident that our tests, which use specific DNA markers to anticipate the effectiveness of particular drugs on a patient, when fully developed and offered to the market, will establish a world standard for theranostic testing and help alleviate the suffering of cancer patients worldwide."

About NeoCodex, Inc.

NeoCodex SL is a biomedical and genomic research 'total solutions provider,' focused on understanding the molecular and genetic basis of human disease, and on employing novel methodologies for the continued improvement of current genetic analysis techniques. Additionally equipped to provide a wide-range of DNA specimens from internally-maintained biological repositories and from prospective collections, NeoCodex remains a leader in the research and support service arenas. For further information, contact Kathleen Bem at 317-727-5962.

About DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS?, RETINOME?, ANCESTRYbyDNA? and EURO-DNA?. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.


Company Contact:

Richard Gabriel
CEO and President
941 366-3400

or

Ron Stabiner
 

DNAPrint Genomics kündigt an, daß strategisches Bündnis mit NeoCodex
Gesellschaft DNSprobe liefert, die für Theranostic Forschung über Ovarian Krebs

SARASOTA, FL testet, -- (22. August 2006 Leitung vermarktet), -dNAPrint Genomics, Inc. (OTCBB: DNAG) heute kündigte an, daß es eine strategische Bündnisvereinbarung mit NeoCodex, Inc. von Sevilla, Spanien unterschrieben hat, um DNSstichprobenerhebung für andauernde Forschung in theranostic Test-/Medikamentenbehandlungen für ovarian Krebs zu liefern.

Hervorgehobene Verbindungen
MacReport.Net
DNAPrint (TM) Genomics, Inc.

unter den Bedingungen der Vereinbarung, NeoCodex Geschäfts, wie Einheiten in Spanien und in den Vereinigten Staaten annehmen, daß das DNS probiert, werden von DNAPrint Genomics für Forschung in die Wirksamkeit von bestimmten Behandlungen für ovarian Krebs getestet, der kombinatorische Behandlungen von Taxotere ®, Taxol ®, Carboplatin und Cisplatin einschließt.

DNAPrint Technologien wenden seinen Beimischungsangleichung (beimengen) Prozeß an, um entsprechende Herkunft zu identifizieren, informative Markierer (Ziele), innerhalb der gerichteten Bevölkerung, um Gene zu identifizieren von, fördern Interesse auf Grundlage von den von NeoCodex gelieferten Medikamentenantwortdaten.

"wir sind äußerst erfreut, mit NeoCodex über diese wichtige Forschung zu kollaborieren," gab DNAPrint Präsidenten und Vorstandsvorsitzenden Richard Gabriel an. "Ein entscheidendes Element jeder Chemotherapiekur identifiziert sofort die Kombinationen von Medikamenten, die den Krebs in Remission bringen. Wir sind zuversichtlich, daß unsere Tests, die bestimmte DNSmarkierer verwenden, um die Wirksamkeit von besonderen Medikamenten auf einem Patienten zu erwarten, wenn vollständig sich entwickelt und dem Markt angeboten, feststellen, daß eine Weltnorm für theranostic, testend, und Hilfe das Leiden von Krebspatienten weltweit lindern, ".

Über NeoCodex ist Inc.

NeoCodex SL eine biomedical und genomic Forschung ' zählt Lösungen zusammen Ernährer, ' zielte, die molekulare und genetische Basis menschlicher Krankheit zu verstehen und neuartige Methodologien für die fortgesetzte Verbesserung von gegenwärtigen genetischen Analysemethoden zu verwenden. Ausgerüstet außerdem dazu, einen breiten Bereich von DNSmustern von innerlich behaupteten biologischen Lagern und von voraussichtlichen Sammlungen zu liefern, bleibt NeoCodex ein Leiter in den Forschungs- und Unterstützungsdienstarenen. Zwecks weiterer Information wenden Sie sich an Kathleen Bem an 317-727-5962 .

über DNAPrint Genomics, Inc.

DNAPrint Genomics, Inc. (ist ein Entwickler von genomics basierten Produkten und Diensten auf zwei Hauptmärkten: biomedical und forensics. DNAPrint Pharmaka, Inc. ein gänzlich besaß Tochtergesellschaft, entwickelt diagnostische Tests und theranostic Produkte (Medikamenten-/Testkombinationen) mit Hilfe von den mit Eigentumscomputationaler Modeliertechnologie verbundenen Eigentumsherkunftsinformierten genetischen Markiererstudien der Gesellschaft. Computationale Biologie und Pharmacogenomics Dienste werden auch äußerlich biopharmaceutical Gesellschaften angeboten. Die Gesellschaft ist erstes theranostic Produkt ist PT -401, ein "super EPO" (erythropoietin) trüberes Eiweißmedikament für Behandlung der Anämie in Nierendialysepatienten (mit Ende inszeniert Nierenkrankheit). Preclinical und kalte Entwicklung von allen, von denen die Medikamentenkandidaten der Gesellschaft profitieren werden, simulierten pre Prüfungen, tatsächliche Prüfungen besser zu gestalten, und sind zu Patienten mit genetischen Profilen gerichtet, die ihre Neigung anzeigen, die am besten kalten Antworten zu haben. DNAPrint ist stolz auf seine fortgesetzte Widmung daran, neue technologische Fortschritte in Gesetzesdurchsetzungs- und Verbraucherherkunftserbinteressen zu entwickeln und zu liefern. Bitte bezieht sich zwecks Information über Gesetzesdurchsetzungs- und Verbraucherbewerbungen, die DNAWITNESST, RETINOMET, ANCESTRYbyDNAT und Euro DNAT enthalten. DNAWitness Y und DNAWitness-Mito sind zwei von der Gesellschaft angebotene Tests. Die Ergebnisse von diesen Tests können als Identifikationswerkzeuge verwendet werden, wenn eine DNSprobe ist, verschlechtert sich, oder testende Kompromisse geschlossene oder andere DNS versäumt, akzeptable Ergebnisse zu bringen.

 

und dann bis ??

 

und dann bis?  

will meine Rente in trockenen Tüchern haben...  

Heute aber locker über die 0,02

jep  

 

hab den ganzen Mist raus

auf zu neuen Taten

Grüße  

hab 50% mit 15% verkauft, Rest bleibt, habe gerade die Konferenz verfolgt, das gibt noch eine Story, sehr interessant und genau mein Ding (Pharma/Biogenetik) :-)).  

und thx RP für den Tipp :-).  

hat sich ja toll entwickelt in den letzten Wochen, nachdem sie spottbillig eine Zeit lang zu haben waren (Schnäppchenpreise *g*), wurde auch Zeit :-).  

Du meinst wohl, nach 3 Jahren Talfahrt sollte endlich mal ein Boden erreicht werden.  

ist doch was, bei 0,007 USD waren die spottbillig, so sehe ich das jedenfalls.  

so langsam kommt DNAG ins Rollen :-).

**************************************************

DNAPrint(TM) Genomics and Code Amber(R) Form Partnership to Offer Storage of DNA Sequencing on Amber Stick(TM)
DNAPrint Also Becomes Sponsor of Code Amber Ticker

SARASOTA, FL and MANDEVILLE, LA -- (MARKET WIRE) -- February 13, 2007 -- DNAPrint? Genomics, Inc. (OTCBB: DNAG) and Code Amber® (www.codeamber.org) today announced a partnership under which consumers would be offered the ability to store a child's DNA sequence on a memory stick for instant accessibility and, at the same time, DNAPrint has become the sponsor of the Code Amber Ticker, a JavaScript news feed ticker that displays active Amber Alerts on an organization's web pages.

In cooperation with Amber Stick? (http://codeamber.org/idkits.html?front), the only child identification system endorsed by Code Amber, DNA sequencing from DNAPrint? will be stored on a flash memory device, along with photos and descriptions of the child.

Code Amber is the most recognized distributor of Amber Alerts on the Internet. With its powerful reach to more than 300,000 web sites and PCs displaying the Code Amber Ticker, millions are alerted when a child is missing or in imminent danger.

"When children are unintentionally separated from their parents by being lost, abducted or the victim of a disaster, time is critical," said Bryant Harper, President of Code Amber. "With all the identifying information stored safely and accurately in one place, parents can assist law enforcement in the crucial first moments of a reported disappearance. We are proud to have DNAPrint as our sponsor and to offer their dynamic technology to everyone."

DNAPrint? is a trusted name with law enforcement agencies. They have offered support to international, federal and local authorities with its DNAWitness? and AncestrybyDNA? products, including federal cases in California and Louisiana, with local police in the Mammoth Lakes (Calif.) Murder Case, and with New Scotland Yard in the United Kingdom in the case of the so-called Minstead Rapist.


Highlighted Links
MacReport.Net

DNAPrint(TM) Genomics, Inc.




"With our close association with the law enforcement community, we have long known that our products were needed in the public sector," stated DNAPrint? CEO and President Richard J. Gabriel. "DNA can be used for more than just identifying suspects, and can be extremely useful in tracking and identifying children after they have gone missing."

Mr. Gabriel continued, "We undertook this sponsorship to provide support for Code Amber. We also see the potential to support the marketing and sales efforts surrounding our consumer products, specifically the Company's proprietary DNA sequencing and storage products. Code Amber is one of many channels that DNAPrint uses to encourage parents to test and store their children's DNA for purposes of identifying certain gene markers that would indicate sensitivity to certain treatments for various diseases, such as an allergic reaction to penicillin, and Amber Stick is uniquely suited to this purpose in addition to being an aid to finding children when they go missing. We hope that parents everywhere will give serious consideration to availing the services available to them with Amber Stick, and we look forward to partnering with Code Amber in the sponsorship of the Code Amber Ticker."

About Code Amber

Based in Mandeville, La., Code Amber is the most recognized distributor of Amber Alerts on the Internet, reaching over 330,000 web sites and personal computers. A leader in the field of child advocacy, Code Amber offers a range of products and services to law enforcement, media, corporations and the public dealing with Amber Alert notification, child safety and information storage. Code Amber's signature Java Script Amber Alert Ticker and XML feed are used throughout North America. For more information, visit www.codeamber.org.

ABOUT DNAPRINT GENOMICS, INC.

DNAPrint Genomics, Inc. (www.dnaprint.com) is a developer of genomics-based products and services in two primary markets: biomedical and forensics. DNAPrint Pharmaceuticals, Inc., a wholly owned subsidiary, develops diagnostic tests and theranostic products (drug/test combinations) using the Company's proprietary ancestry-informed genetic marker studies combined with proprietary computational modeling technology. Computational Biology and Pharmacogenomics services are also offered externally to biopharmaceutical companies. The Company's first theranostic product is PT-401, a "Super EPO" (erythropoietin) dimer protein drug for treatment of anemia in renal dialysis patients (with end stage renal disease). Preclinical and clinical development of all the Company's drug candidates will benefit from simulated pre-trials to design actual trials better and are targeted to patients with genetic profiles indicating their propensity to have the best clinical responses. DNAPrint is proud of its continued dedication to developing and supplying new technological advances in law enforcement and consumer ancestry heritage interests. Please refer to www.dnaprint.com for information on law enforcement and consumer applications which include DNAWITNESS?, RETINOME?, ANCESTRYbyDNA? and EURO-DNA?. DNAWitness-Y and DNAWitness-Mito are two tests offered by the Company. The results from these tests may be used as identification tools when a DNA sample is deteriorated or compromised or other DNA testing fails to yield acceptable results.

Forward-Looking Statements

All statements in this press release that are not historical are forward-looking statements. Such statements are subject to risks and uncertainties that could cause actual results to differ materially from those projected, including, but not limited to, uncertainties relating to technologies, product development, manufacturing, market acceptance, cost and pricing of DNAPrint's products, dependence on collaborations and partners, regulatory approvals, competition, intellectual property of others, and patent protection and litigation. DNAPrint Genomics, Inc. expressly disclaims any obligation or undertaking, except as may be required by applicable law or regulation to release publicly any updates or revisions to any forward-looking statements contained herein to reflect any change in DNAPrint's expectations with regard thereto or any change in events, conditions, or circumstances on which any such statements are based.
 

durch den Verkauf der Biofrontera-Anteile für ca. 6 Mio USD, bei einer MK von ca. 7 Mio USD momentan ist das nicht schlecht. Also, die Liquidität ist vorerst gesichert.

**************************************************

Form 8-K for DNAPRINT GENOMICS INC


--------------------------------------------------

5-Mar-2007

Completion of Acquisition or Disposition of Assets



Item 2.01 Completion of Acquisition or Disposition of Assets.
On February 27, 2007, the Registrant entered into a contract to dispose of, and completed the disposition of, 373,324 shares of Biofrontera AG. The contract, with Matchmakers Consulting AG, a Swiss corporation, provides for the payment to the Registrant of an aggregate of ?4,443,240 (approximately $5.9 million).
The DZ Bank AG Deutsche Zentral-Genossenschaftsbank has released the Registrant from the lock-up agreement regarding the shares after the Swiss corporation entered into a similar lock-up agreement. An installment of ?500,000 (approximately $659,000) was paid simultaneously with the execution of the agreement.
The remainder of the purchase price will be paid in seven monthly installments of ?500,000 (approximately $659,000) each in the months of March through September, 2007, with a final installment of ?443,240 (approximately $584,000) due on October 31, 2007.

In addition, by October 31, 2007, the Registrant has the right to irrevocably announce a repurchase of any or all of the shares sold in this transaction at a purchase price of ?16.13 per share.
If exercised in full, this repurchase right would require payment of an aggregate repurchase price of ?6,005,586
(approximately $7.9 million).
The repurchase would then be executed between October 31, 2007 and March 31, 2008.

 

Bin schon am 27.9. für 0,4 Cent eingestiegen, nachdem ich mich auf der Homepage des Unternehmens davon überzeugt hatte, dass die überhaupt noch arbeiten... ;-)

Ansonsten eher eine gefühlsmäßige Entscheidung und ein Betrag, den ich voraussichtlich nicht innerhalb der nächsten drei bis vier Jahre unbedingt brauche bzw. dessen Verlust mich nicht umbringen würde.

Ein bisschen wie Roulette...